Management of Metastatic Castration-resistant Prostate Cancer | Zendy

Emmanuel S. Antonarakis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Management of Metastatic Castration-resistant Prostate Cancer

Author(s) -

Emmanuel S. Antonarakis

Publication year - 2011

Publication title -

european oncology and haematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.116

H-Index - 6

eISSN - 2045-5283

pISSN - 2045-5275

DOI - 10.17925/eoh.2011.07.04.251

Subject(s) - cabazitaxel , medicine , prostate cancer , abiraterone acetate , denosumab , enzalutamide , oncology , clinical trial , cancer , intensive care medicine , androgen deprivation therapy , osteoporosis , androgen receptor

The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forward in the last 2 years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel, and abiraterone acetate), and a significant delay in skeletal-related events observed with denosumab. The pipeline of systemic therapies in prostate cancer remains strong, as multiple agents with a diverse array of mechanisms of action are demonstrating preliminary signs of clinical benefit, leading to more definitive phase III confirmatory trials. In this review, we will discuss the evolving landscape of treatment options for men with CRPC, with a particular focus on currently approved and emerging treatment options for these patients. Knowledge of these evolving standards will help to optimize delivery of care and long term outcomes in men with advanced CRPC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research